Literature DB >> 25219649

Metformin: a potential drug to treat hyperpigmentation disorders.

Elisabeth S Belisle1, Hee-Young Park2.   

Abstract

Hyperpigmentation disorders are generally difficult to treat because of the limited availability of effective therapeutics with minimal side effects. In this issue, Lehraiki et al. report that metformin, an antidiabetic drug, inhibited melanogenesis, in vitro and in vivo, and they suggest that metformin may be used to treat hyperpigmentation disorders. This commentary reviews the molecular mechanisms through which metformin inhibits melanogenesis and examines metformin as a potential drug to treat hyperpigmentation.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25219649     DOI： 10.1038/jid.2014.245

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  9 in total

1.  MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes.

Authors:  Hee-Young Park; Christina Wu; Laurie Yonemoto; Melissa Murphy-Smith; Heng Wu; Christina M Stachur; Barbara A Gilchrest
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

2.  Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.

Authors:  Battsetseg Batchuluun; Toyoshi Inoguchi; Noriyuki Sonoda; Shuji Sasaki; Tomoaki Inoue; Yoshinori Fujimura; Daisuke Miura; Ryoichi Takayanagi
Journal:  Atherosclerosis       Date:  2013-11-05       Impact factor: 5.162

3.  Inhibition of melanogenesis by the antidiabetic metformin.

Authors:  Abdelali Lehraiki; Patricia Abbe; Michael Cerezo; Florian Rouaud; Claire Regazzetti; Bérengère Chignon-Sicard; Thierry Passeron; Corine Bertolotto; Robert Ballotti; Stéphane Rocchi
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

Review 4.  Cellular and molecular mechanisms of metformin: an overview.

Authors:  Benoit Viollet; Bruno Guigas; Nieves Sanz Garcia; Jocelyne Leclerc; Marc Foretz; Fabrizio Andreelli
Journal:  Clin Sci (Lond)       Date:  2012-03       Impact factor: 6.124

5.  p38 regulates pigmentation via proteasomal degradation of tyrosinase.

Authors:  Barbara Bellei; Vittoria Maresca; Enrica Flori; Angela Pitisci; Lionel Larue; Mauro Picardo
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

6.  Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation.

Authors:  Hee-Young Park; Jin Lee; Salvador González; Maritza A Middelkamp-Hup; Sameer Kapasi; Shaun Peterson; Barbara A Gilchrest
Journal:  J Invest Dermatol       Date:  2004-01       Impact factor: 8.551

7.  Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.

Authors:  Gaël G McGill; Martin Horstmann; Hans R Widlund; Jinyan Du; Gabriela Motyckova; Emi K Nishimura; Yi-Ling Lin; Sridhar Ramaswamy; William Avery; Han-Fei Ding; Siobhán A Jordan; Ian J Jackson; Stanley J Korsmeyer; Todd R Golub; David E Fisher
Journal:  Cell       Date:  2002-06-14       Impact factor: 41.582

8.  Activation of cAMP-dependent protein kinase is required for optimal alpha-melanocyte-stimulating hormone-induced pigmentation.

Authors:  Y Ao; H Y Park; S Olaizola-Horn; B A Gilchrest
Journal:  Exp Cell Res       Date:  1998-10-10       Impact factor: 3.905

9.  Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.

Authors:  Russell A Miller; Qingwei Chu; Jianxin Xie; Marc Foretz; Benoit Viollet; Morris J Birnbaum
Journal:  Nature       Date:  2013-01-06       Impact factor: 49.962
  9 in total
  1 in total

1.  Metformin - For the dermatologist.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Pharmacol       Date:  2016 Jan-Feb       Impact factor: 1.200
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.